Sichuan Kelun Pharmaceutical Co., Ltd. (SHE:002422)

China flag China · Delayed Price · Currency is CNY
32.60
-0.64 (-1.93%)
Apr 28, 2026, 3:04 PM CST
-1.63%
Market Cap 51.85B
Revenue (ttm) 18.38B
Net Income (ttm) 1.57B
Shares Out 1.59B
EPS (ttm) 0.99
PE Ratio 32.92
Forward PE 23.27
Dividend 0.59 (1.79%)
Ex-Dividend Date n/a
Volume 13,008,618
Average Volume 20,747,220
Open 33.15
Previous Close 33.24
Day's Range 32.54 - 33.95
52-Week Range 28.14 - 41.72
Beta -0.13
RSI 42.64
Earnings Date Apr 3, 2026

About SHE:002422

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumo... [Read more]

Sector Healthcare
Founded 1996
Employees 20,127
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002422
Full Company Profile

Financial Performance

In 2025, SHE:002422's revenue was 18.51 billion, a decrease of -15.13% compared to the previous year's 21.81 billion. Earnings were 1.70 billion, a decrease of -42.03%.

Financial Statements

News

Sichuan Kelun Pharmaceutical Earnings Call Transcript: H2 2025

Revenue grew 6.5% to RMB 2.06 billion in 2025, driven by expanded commercialization and strong R&D pipeline. Gross margin outpaced revenue growth, but net loss increased due to higher sales and R&D expenses. Multiple new approvals, global partnerships, and AI-driven R&D position the company for further growth.

5 weeks ago - Transcripts

Sichuan Kelun Pharmaceutical Transcript: 44th Annual J.P. Morgan Healthcare Conference

The company highlighted its leadership in ADC innovation, with four approved products and a robust pipeline targeting oncology and beyond. Strategic partnerships and inclusion in China's NRDL 2025 support commercialization and global expansion.

3 months ago - Transcripts

Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up

(RTTNews) - Crescent Biopharma, Inc. (CBIO), on Thursday announced an exclusive partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize oncology therapeutics, i...

5 months ago - Nasdaq

Sichuan Kelun Pharmaceutical Earnings Call Transcript: H1 2025

Reported RMB 950 million revenue in 1H 2025, driven by first-year commercialization and robust R&D partnerships. Lung cancer led sales, with strong clinical progress and a solid cash position supporting future growth.

9 months ago - Transcripts